AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 182 min read$CORT

Corcept's Lifyorli Gets Positive EU Opinion For Platinum-Resistant Ovarian Cancer

Corcept Therapeutics (CORT) announced that the EMA's CHMP recommended approval of relacorilant for platinum-resistant ovarian cancer, based on Phase 2 and 3 trial data showing improved survival rates. The European Commission will decide by Q4 2026. CORT's stock closed at $114.86, up 2.73%, and was at $115.45 in premarket trading.

Original reporting
rttnews.com
Published Sep 18, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 1:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$CORT
Bullish
high confidence
Mentioned
$CORT
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$CORTBullishMed
01

Why it matters

The CHMP opinion is a key regulatory milestone that could unlock a sizable European market and improve the company's valuation.

02

Market read

Regulatory progress for a late‑stage oncology drug is a high‑impact event for the stock and the broader oncology biotech sector.

03

What to watch

Potential competition from other platinum‑resistant ovarian cancer agents and reimbursement uncertainties.

Relevance 8/10Novelty 8/10Timing: premarket today

Background

Corcept Therapeutics focuses on cortisol‑modulating drugs; relacorilant (Lifyorli) is its lead oncology candidate.

Company-level read

Ticker impact

$CORTBullishHigh confidence
Context

EU CHMP issued a positive opinion on relacorilant for platinum‑resistant ovarian cancer, a first regulatory step toward approval.

Expected impact

Short‑term upside as investors price in possible approval; long‑term upside if EU launch proceeds.

Evidence & confidence

Regulatory endorsement is a material catalyst for a biotech; the drug targets an unmet need and the trial showed survival benefit.

Market effects

Sector

Positive signal for ovarian‑cancer therapeutics may lift peer biotech stocks in oncology.

Regional

EU biotech sector could see modest gains as investors anticipate a new approved product.

Global

Adds to global pipeline confidence for glucocorticoid‑receptor modulators.

Counterpoint

What could challenge this read

If EMA delays final approval or imposes restrictive labeling, the initial optimism could reverse.

Key entities

  • company
    Corcept Therapeutics Inc.

    Biopharma developing relacorilant for oncology and endocrine disorders.

  • regulator
    European Medicines Agency (EMA)

    EU authority that issued the positive CHMP opinion.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 23
$CORTHighAI 8/10

Why is Corcept Therapeutics stock tumbling today?

Corcept Therapeutics (CORT) shares fell 12.9% after Genmab's rival drug showed positive results in a Phase 3 trial for platinum-resistant ovarian cancer, directly competing with Corcept's Lifyorli. The decline was exacerbated by prior downgrades and market headwinds, with shares dropping from $106.05 to a low of $90.99 before partially recovering to $93.68.

investing.com2 min
SEP 22
$CORTHighAI 8/10

Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle

Corcept Therapeutics (CORT) announced that Europe's drug regulator recommended approval for its cancer therapy, relacorilant, for use with chemotherapy in platinum-resistant ovarian cancer. The recommendation is based on a Phase 3 trial showing improved patient outcomes. The European Commission's final decision is expected in Q4 2026. Corcept reported $47.6M in Q2 revenue from Lifyorli (relacorilant) and raised its full-year revenue guidance to $1.1B-$1.2B, with net income increasing to $43M.

insidermonkey.com3 min
SEP 19
$CORTHighAI 8/10

CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally

Corcept Therapeutics (CORT) shares rose 7% to their highest 2026 levels after announcing plans to resubmit its NDA for Relacorilant, a Cushing’s syndrome treatment, following positive FDA discussions. The FDA rejected the initial filing in December, citing insufficient effectiveness data. The company expects a PDUFA date six months post-submission. CORT shares are down 27% year-to-date, with retail sentiment remaining bearish.

stocktwits.com2 min
SEP 18
$CORTHighAI 9/10

Corcept Therapeutics Incorporated: Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli (Relacorilant)

Corcept Therapeutics (CORT) announced the European Medicines Agency's CHMP recommended EU approval for relacorilant, combined with nab-paclitaxel, to treat platinum-resistant ovarian cancer. The recommendation follows positive Phase 2 and Phase 3 trial results showing improved survival rates. The EC will decide by Q4 2026. Relacorilant is already FDA-approved in the U.S. for the same indication.

finanznachrichten.de2 min
AUG 6
$CORTHighAI 9/10

Raised Guidance Lifts Corcept to 52-Week High

Corcept Therapeutics (CORT) reported fiscal 2026 Q2 results with record revenue of $256.1 million, up 32% year over year, and net income of $43 million, up 22.9%. The company had $545 million in cash and investments and raised 2026 revenue guidance to as much as $1.2 billion, sending shares to a 52-week high.

yahoo.com3 min
JUL 31
$MSFTHighAI 8/10

Stocks Rally on Stellar Microsoft Earnings and Chip Stock Strength

US stocks rose as investors digested strong Q2 earnings expectations and results, led by Microsoft. The article cites Bloomberg Intelligence forecasts for Q2 earnings up about 23% and notes 86% of 243 S&P 500 firms beat estimates. It also reports chip and AI-infrastructure gains tied to Lam Research and other semis, while some software names fell.

yahoo.com7 min